Arthur He CFA, an analyst from H.C. Wainwright, reiterated the Buy rating on Nektar Therapeutics (NKTR – Research Report). The associated price target remains the same with $6.50.
Arthur He CFA has given his Buy rating due to a combination of factors including Nektar Therapeutics’ strategic collaboration with TrialNet to evaluate rezpeg for type 1 diabetes (T1D). This partnership allows Nektar to advance their clinical trials without using their own funds, which is a significant advantage. The study is designed to assess the efficacy of rezpeg in treating T1D, potentially providing a new therapeutic option for the approximately 2 million Americans living with the condition.
Moreover, the scientific rationale for rezpeg’s use in T1D is strong, as it has shown promise in preclinical and clinical studies by selectively stimulating regulatory T cells and improving inflammatory conditions. The involvement of TrialNet, a leading organization in T1D research, further strengthens the potential success of the study due to their extensive experience and resources. Arthur He’s valuation also considers a risk-adjusted net present value analysis, which supports the $6.50 price target, while acknowledging risks such as clinical, regulatory, and competitive challenges.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $7.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com